\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationHybrid
The European Cancer Organisation is organising the European Cancer Summit 2025, convening the broad cancer community to chart a new path forward. The Summit will focus on the urgent need to secure sustained political and financial support for cancer as a health and societal priority. This multistakeholder forum provides the setting for healthcare professionals, patients and policymakers to tackle challenges from every perspective and work together towards developing solutions and uncovering opportunities.
On the agenda, among others, sessions on 'AI and Cancer Care: A Paradigm Shift in Progress' and on 'Bringing European Cancer Research to the Next Level: Cooperation, Innovation and Transformation', with the key note address by European Commissioner for Startups, Research and Innovation, Ekaterina Zaharieva.
More information, the detailed agenda and registration on the event webpage. Note that this is a paying event.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
